Featured Research

from universities, journals, and other organizations

New Platinum-based Anti-tumor Compound Developed

Date:
February 21, 2009
Source:
Wake Forest University
Summary:
Researchers have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

The results were published in the December 11 issue of the Journal of Medicinal Chemistry and highlighted in Science-Business eXchange (SciBX), produced by Nature Publishing Group and BioCentury Publications, Inc. They suggest a new approach to fighting non-small cell lung cancer, which accounts for more than three-quarters of all lung cancers. Lung cancer is the leading cause of cancer-related deaths in both men and women. Less than a third of non-small cell lung cancer patients respond to traditional platinum-based therapies, and those who do respond have a median survival of less than a year.

“We are able to slow the growth of this cancer substantially in mice,” said principal investigator Ulrich Bierbach, Z. Smith Reynolds Foundation Fellow and associate professor of chemistry at Wake Forest. “That is very good news, since this is such a rapidly growing, intractable type of cancer.”

The new compound’s potency derives from its ability to rapidly bind with and disable a tumor cell’s DNA before the cell’s natural repair mechanisms are activated. That repair process causes drug resistance, which reduces the effectiveness of currently used platinum-based drugs.

Bierbach has focused his research efforts since 1992 on finding ways to overcome the resistance problems inherent in platinum-based drugs. He joined the Wake Forest faculty in 1999, and since 2001, has led a research team that included participation by eight graduate students and more than 30 undergraduate students. The recent paper marks the 25th he has published on the topic.

“If this ends up in clinical trials in the next few years, that will fulfill a dream of mine,” Bierbach said.

His research efforts will now be directed toward finding ways to boost the tumor-killing potency of the new compounds while reducing harmful side effects.

The new hybrid compounds are available for licensing from the Wake Forest University Office of Technology Asset Management.


Story Source:

The above story is based on materials provided by Wake Forest University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zhidong Ma, Jayati Roy Choudhury, Marcus W. Wright, Cynthia S. Day, Gilda Saluta, Gregory L. Kucera, Ulrich Bierbach. A Non-Cross-Linking Platinum-Acridine Agent with Potent Activity in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2008; 51 (23): 7574 DOI: 10.1021/jm800900g

Cite This Page:

Wake Forest University. "New Platinum-based Anti-tumor Compound Developed." ScienceDaily. ScienceDaily, 21 February 2009. <www.sciencedaily.com/releases/2009/02/090211193818.htm>.
Wake Forest University. (2009, February 21). New Platinum-based Anti-tumor Compound Developed. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/02/090211193818.htm
Wake Forest University. "New Platinum-based Anti-tumor Compound Developed." ScienceDaily. www.sciencedaily.com/releases/2009/02/090211193818.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins